OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SRSF10 stabilizes CDC25A by triggering exon 6 skipping to promote hepatocarcinogenesis
Xiaoming Liu, Yongqiang Zheng, Mengqing Xiao, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 15

Showing 15 citing articles:

Alternative splicing and related RNA binding proteins in human health and disease
Yining Tao, Qi Zhang, Haoyu Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 50

The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2
Yingwei Li, Zhongshao Chen, Jiali Peng, et al.
Oncogene (2023) Vol. 42, Iss. 31, pp. 2386-2401
Closed Access | Times Cited: 11

Alternative splicing: a bridge connecting NAFLD and HCC
Kequan Xu, Tiangen Wu, Peng Xia, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 10, pp. 859-872
Open Access | Times Cited: 10

SRSF10 regulates proliferation of neural progenitor cells and affects neurogenesis in developing mouse neocortex
Junjie Li, Hanyang Jiang, Ya-Wei Mu, et al.
iScience (2023) Vol. 26, Iss. 7, pp. 107042-107042
Open Access | Times Cited: 5

SRSF10 facilitates HCC growth and metastasis by suppressing CD8+T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy
Xiangyuan Luo, Zerui Zhang, Siwen Li, et al.
International Immunopharmacology (2023) Vol. 127, pp. 111376-111376
Open Access | Times Cited: 4

Targeting serine- and arginine-rich splicing factors to rectify aberrant alternative splicing
Dianyang Li, Wenying Yu, Maode Lai
Drug Discovery Today (2023) Vol. 28, Iss. 9, pp. 103691-103691
Closed Access | Times Cited: 3

Decoding the role of aberrant RNA alternative splicing in hepatocellular carcinoma: a comprehensive review
Mengfei Sheng, Yuanyuan Zhang, Yaoyun Wang, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 19, pp. 17691-17708
Closed Access | Times Cited: 3

Assessing the Impact of Novel BRCA1 Exon 11 Variants on Pre-mRNA Splicing
Halla Elshwekh, Inas Alhudiri, Adam Elzagheid, et al.
Cells (2024) Vol. 13, Iss. 10, pp. 824-824
Open Access

Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing
Ji Zhang, Xinyu Xu, Hong‐Wei Deng, et al.
Pharmacology & Therapeutics (2024) Vol. 261, pp. 108697-108697
Closed Access

Exploring serine-arginine rich splicing factors: potential predictive markers for dysregulation in oral cancer
Sakshi Sharma, Manasi Mittal, Akanksha Shukla, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access

Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges
Qi Jia, Xiaoxiao Sun, Haoyu Li, et al.
Gut (2024), pp. gutjnl-333127
Closed Access

SRSF10 inhibition prevents HCC growth and metastasis and enhances the anti-PD-L1- mediated tumor suppression
Xiangyuan Luo, Zerui Zhang, Yijun Wang, et al.
Research Square (Research Square) (2023)
Closed Access

Page 1

Scroll to top